Salamanca

• A study to compare Venetoclax Azacitidine and Quizartinib Vs Venetoclax and Azacitidine in newly diagnosed acute myeloid leukemia patient´s … Recruiting
  2025-522979-29-00 5 2026-04-30 Acute myeloid leukemia
• An early Phase 1b Study to assess how safe and effective is the treatment with drugs, called Mosunetuzumab or Glofitamab in Combination with … Recruiting
  2023-505185-28-00 3 2026-04-23 Non-Hodgkin Lymphoma
• A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosi … Recruiting
  2025-521546-23-00 5 2026-04-21 Secondary progressive multiple sclerosis
• Pacritinib for Patients With Myelofibrosis Who Have Thrombocytopenia Recruiting
  2025-522509-39-00 4 2026-03-30 Patients with myelofibrosis and platelets counts between 50 - 120 x 10
• Evaluation of efficacy and safety of early in hospital initiation of inclisiran treatment in patients with acute coronary syndromes Recruiting
  2025-521670-34-00 5 2026-03-04 Acute coronary syndrome (ST-elevation myocardial infarction [STEMI] or
• A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratum … Recruiting
  2025-520897-21-00 10 2026-02-25 Multiple Myeloma
• Lp(a) lowering study of pelacarsen (TQJ230) with background inclisiran in participants with elevated Lp(a) and established ASCVD Recruiting
  2024-516356-18-00 5 2026-02-17 Atherosclerotic cardiovascular disease (ASCVD)
• LOW DOse vs standard dose and administration TIme in near-infrared fluorescence cholangiography during laparoscopic cholecystectomy: a rando … Recruiting
  2025-522535-33-00 6 2026-02-13 Symptomatic Cholelithiasis
• ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting
  2025-522960-34-00 5 2026-02-09 Established cardiovascular disease
• Phase 1b/2a Study to Evaluate Mezigdomide in Combination with Elranatamab in Relapsed and/or Refractory Multiple Myeloma Recruiting
  2025-522090-11-00 9 2026-01-22 Relapsed or Refractory Multiple Myeloma (RRMM)
• A trial to learn how safe AZD4512 is and how it works in the bodies of people with B-cell acute lymphoblastic leukemia (B-ALL) Recruiting
  2025-522372-93-00 7 2026-01-13 B-cell acute lymphoblastic leukemia (B-ALL)
• A medical study testing the safety and effectiveness of BP1.4979, a new drug for adults with obsessive-compulsive disorder. Recruiting
  2025-522026-13-00 4 2026-01-12 Obsessive compulsive disorder
• A Follow-up Study of Mezagitamab in Adults with Chronic Primary Immune Thrombocytopenia Recruiting
  2025-521692-31-00 5 2025-12-19 Chronic Primary Immune Thrombocytopenia
• Efficacy of Tuvusertib in Recurrent IDH mutant Astrocytoma with ATRX mutation, a phase II prospective trial. Recruiting
  2025-521843-19-00 4 2025-12-19 IDH1/2-mutated, ATRX-mutated and p53-mutated astrocytoma
• ENGIC 06 (PRODIGE 114) – FFCD 2401 – FRUQUITAS Randomized phase III trial to compare trifluridine/tipiracil + Fruquintinib versus triflurid … Recruiting
  2025-522395-92-00 5 2025-12-15 metastatic oeso-gastric adenocarcinoma
• A randomized, double-blinded, placebo-controlled trial to evaluate the efficacy and safety of ninerafaxstat in patients with symptomatic non … Recruiting
  2024-515125-28-00 4 2025-12-08 Non-obstructive hypertrophic cardiomyopathy
• A Follow-Up Shiftability Study of Arbaclofen with an Open-Label Extension for the study of Biomarkers for Treatment for Social Function in C … Recruiting
  2023-508407-20-00 5 2025-11-20 autism spectrum disorder
• A Study to Evaluate the Efficacy and Safety of Mezagitamab Subcutaneous Injection Compared With Placebo in Adults With Chronic Immune Thromb … Recruiting
  2024-514401-54-00 5 2025-11-13 Chronic Primary Immune Thrombocytopenia
• A clinical study of sac-TMT in people with breast cancer (MK-2870-032) Recruiting
  2024-520190-12-00 5 2025-11-10 Breast Cancer: triple negative breast cancer (TNBC) and hormone recept
• A Study to Learn About the Study Medicine Called PF-07248144 in Combination with Fulvestrant in People with HR-positive, HER2-negative Advan … Recruiting
  2025-520566-22-00 5 2025-11-10 Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Ca
• A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax P … Recruiting
  2024-517131-52-00 5 2025-11-03 Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lym
• A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated with Alzheimer’s Disease. Recruiting
  2025-520613-31-00 5 2025-10-31 Agitation Associated with Alzheimer’s Disease
• TRITON-CM: A Study to Evaluate Nucresiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy Recruiting
  2024-519917-72-00 5 2025-10-29 Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
• A research study looking at how different doses of study medicine (Inno8) work in the body of people with haemophilia A Recruiting
  2025-520490-38-00 3 2025-10-13 Haemophilia A with or without inhibitors. Proposed indication under de

Showing 73–96 of 470 trials